Our Pipeline

Target class

Indication

Molecule

Program

Discovery

Preclinical

Phase i/ii

Phase iii

Cytokine

Solid tumors

Skin cancer

Lung cancer

IL-12

ANK-101

Antibody

Solid tumors

Agonist

(Full-length Ab)

Inhibitor

(Nanobody)

ANK-201

ANK-202

ANK-203

Small Molecule

Solid tumors

Agonist

ANK-301

ANK-302

Lead Product Candidate: IL-12 Anchored-Drug Conjugate (ANK-101)

  • IL-12 is a cytokine with anti-tumor effects in preclinical and clinical settings
  • Systemic IL-12 is highly toxic

ANK-101

  • IL-12 bound to the anchor, aluminum hydroxide (Alhydrogel®) ​
  • Retained at the tumor site > 28 days in preclinical models
  • Potent single-dosing therapeutic activity as a monotherapy and in combination with other agents in multiple murine tumor models
  • Has favorable safety profile (no dose-limiting toxicities) in mice, dogs, and non-human primates